CN112190603A - Phytolacca acinosa fruit fermentation liquor and preparation method and application thereof - Google Patents
Phytolacca acinosa fruit fermentation liquor and preparation method and application thereof Download PDFInfo
- Publication number
- CN112190603A CN112190603A CN202011079683.6A CN202011079683A CN112190603A CN 112190603 A CN112190603 A CN 112190603A CN 202011079683 A CN202011079683 A CN 202011079683A CN 112190603 A CN112190603 A CN 112190603A
- Authority
- CN
- China
- Prior art keywords
- fermentation
- fruit
- fresh
- preparation
- aspergillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 152
- 230000004151 fermentation Effects 0.000 title claims abstract description 149
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 240000008013 Phytolacca acinosa Species 0.000 title claims description 24
- 235000009076 Phytolacca acinosa Nutrition 0.000 title claims description 24
- 240000007643 Phytolacca americana Species 0.000 claims abstract description 87
- 235000009074 Phytolacca americana Nutrition 0.000 claims abstract description 87
- 239000007788 liquid Substances 0.000 claims abstract description 63
- 235000021022 fresh fruits Nutrition 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 15
- 241000191335 [Candida] intermedia Species 0.000 claims abstract description 14
- 241000134912 Aspergillus penicillioides Species 0.000 claims abstract description 13
- 241001277988 Aspergillus sydowii Species 0.000 claims abstract description 13
- 241001611341 Penicillium sublateritium Species 0.000 claims abstract description 10
- 241000133627 Aspergillus parvulus Species 0.000 claims abstract description 9
- 241000235048 Meyerozyma guilliermondii Species 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 235000021552 granulated sugar Nutrition 0.000 claims description 12
- 239000012452 mother liquor Substances 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 241000228212 Aspergillus Species 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 7
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 241001508815 Lodderomyces Species 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000010564 aerobic fermentation Methods 0.000 claims description 4
- 150000004056 anthraquinones Chemical class 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 4
- 150000002338 glycosides Chemical class 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 239000004254 Ammonium phosphate Substances 0.000 claims description 3
- 241001508814 Lodderomyces elongisporus Species 0.000 claims description 3
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 3
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 241000576296 Golubevia Species 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 7
- 238000011049 filling Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 241000228143 Penicillium Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 4
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 description 4
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 4
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000252210 Cyprinidae Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000299452 Gouania lupuloides Species 0.000 description 1
- 235000000292 Gouania lupuloides Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241001464778 Zymobacter Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Virology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pokeberry fruit fermentation liquid and a preparation method thereof, the pokeberry fruit fermentation liquid is prepared by adopting a mixed strain fermentation method, the method takes mature pokeberry fresh fruit as a raw material, takes Penicillium sublateritium, Golubeville pallens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozyma guilliermondii, Candida intermedia, Loddermomyces elongii and Aspergillus sydowii 8 mixed strains as fermentation strains, and the pokeberry fruit fermentation liquid is prepared by secondary fermentation at 18-32 ℃. The preparation method has definite fermentation strain and controllable process. The prepared fermentation liquor has clear chemical components and obvious anticancer activity.
Description
Technical Field
The invention belongs to the fields of biological medicines, foods and health-care products, and particularly relates to pokeberry fruit fermentation liquor, a preparation method thereof and application thereof in preparing medicines, foods and health-care products for treating cancers.
Background
Phytolaccae acinosa Radix is a traditional Chinese medicine, is taken as a medicine by roots of years, is bitter and cold, enters lung, spleen, kidney and large intestine channels, has the effects of expelling water and reducing swelling, detoxifying and resolving masses and inducing diuresis, is externally used for detoxifying and resolving masses, is used for treating symptoms such as edema, turgor, carbuncle and swelling, and is also used for treating diseases such as liver ascites type tumor, edema in modern clinic. Phytolacca acinosa is originally recorded in Shen nong Ben Cao Jing (Shen nong's herbal Jing), listed as the first-generation product, and recorded as "Phytolacca acinosa, pungent and mild flavor, mainly manifested as water swelling and tumor arthralgia, removing carbuncle and swelling, and killing ghost essence". The Chinese generation recorded in famous medical records that the pokeberry root has sour flavor and treats pathogenic qi in the chest, edema, paralysis, abdominal fullness, five internal organs and water and qi dispersing. The jin Dynasty Ku hong (elbow posterior prescription) records: for swelling, swollen and swollen, the surface is flooded, radix Phytolaccae is cooked to be thoroughly cooked (peeled and thinly cut), mutton is added for one jin, and salted with scallion, so that the treatment is performed randomly, and the treatment is suitable for treating swelling and healing after eating. Also can be pounded into pokeberry and mixed with rice to be steamed into cake for eating. The Chinese herbal medicine has the following characteristics: the prescription is not used much, but edema is treated, roots are cut, and the mixed carps are boiled to be taken as soup. Taoist-jia is used in powder form, and decocted … … is used as a miraculous drug. The flower is called Yao Hua, especially Lian. The chapter willow, seed, root, seedling and stem in the book Ji ban Ben Cao can be steamed and eaten.
The Chinese pharmacopoeia stipulates that the original plant source of the pokeberry has 2 varieties, namely pokeberry Phytolacca acinosa Roxb and Phytolacca americana L, but the toxicity of the two varieties is different obviously. According to the herbal examination and modern research, the toxicity of pokeberry is low, so that pokeberry is used as a food material, while the toxicity of serendipity is severe. In long-term mixed use, the traditional Chinese medicine generally considers that the traditional Chinese medicine is a toxic traditional Chinese medicine and can cause symptoms such as vomit, headache, diarrhea and the like, so the traditional Chinese medicine is rarely used or is limited to use clinically. However, it is commonly used in national medicine, such as Yi nationality, Mongolian nationality, Tujia nationality and Miao nationality. South China recorded Lei Gong Pao Zhi Lun recorded that "Shang Lu Hua Bai, which the celestial being collected as preserved fruit after more years, can also drink wine. Tang Dynasty Sun Simiao (thousand gold wing prescription) the root seedling can be eaten with purple color, the one with better taste is more superior than white, and the herb is clean, thoroughly steamed and nontoxic. Then, the use of phytolacca esculenta diet therapy is available. To the Song Dynasty "Taiping Shenghui Fang" (Taiping Shenghui Fang): "improving eyesight and benefiting hearing" is more clear to think that it has tonifying action. Shang Lu Xiren also breeds vegetables in the compendium of materia Medica of Ming Dynasty Li Shizhen, white root and purple are taken as tillering seeds for ridge cultivation or seeds. The seedlings can be washed and steamed or cooked well with ash, so they are suitable for people who eat Dansha and Rushi.
The pokeberry is a perennial plant, the infructescence of the pokeberry is terminal or lateral and umbrella-shaped, the annual yield of a single mature fresh fruit is 5-15 kg, the pokeberry can be continuously grown for many years, the yield is extremely high, the resources are rich, but the fresh fruit of the pokeberry is not effectively developed and utilized all the time. The method is characterized in that fresh Phytolacca acinosa Roxb, which is low in toxicity, is used as a raw material, and the fresh fruit contains a large amount of pectin polysaccharide, protein, trace elements and the like besides chemical components of saponins, flavonoids, anthraquinones, phenolic acids and sterols which are consistent with those in roots, so that sufficient nutrient substances can be provided for fermentation, and in addition, the fresh fruit contains rich natural symbiotic strains, so that a condition guarantee is provided for fermentation of the fresh fruit. The fermented fresh fruit fermentation liquor has the effects of removing water and swelling, and resolving hard mass and relieving pain, and is used for treating cancer, AIDS, arteriosclerosis, skin diseases and the like in China folk, and the curative effect is obvious.
Disclosure of Invention
The invention provides a pokeberry fruit fermentation liquid and a preparation method thereof, and separates and identifies mixed fermentation strains and therapeutic active ingredients in the fermentation liquid, thereby obtaining a fermentation process which is controllable, has definite fermentation products, can be used for treating serious and difficult diseases such as cancer, AIDS, arteriosclerosis, skin diseases and the like, and provides a new solution for clinic.
In a first aspect, the invention provides a method for preparing a fermentation liquid of fresh pokeberry fruit, which comprises the following steps:
(1) preparation of fermentation mother liquor: crushing and naturally fermenting mature and fresh pokeberry fruit, continuously stirring, adding a proper amount of inorganic salt and white granulated sugar to adjust culture conditions, and fully fermenting to obtain fermentation mother liquor;
(2) preparation of a first fermentation broth: taking fresh and mature pokeberry fruit, cleaning, draining, drying in the shade until the pokeberry fruit becomes dry, placing in a non-iron fermentation container, adding 2-3% of fermentation mother liquor, uniformly mixing with the pokeberry fruit, carrying out aerobic fermentation for 30-60 days at 20-30 ℃, adding a proper amount of white granulated sugar and organic acid to adjust sugar degree and acidity, and separating fermentation liquor to obtain first fermentation liquor;
(3) preparation of a second fermentation liquid: and placing the primary fermentation liquor in a non-iron container, placing the container in a cold place at 5-25 ℃, sealing in the dark, standing, and fully fermenting for more than 30 days under an anaerobic condition to obtain secondary fermentation liquor, namely the pokeberry fruit fermentation liquor.
In one embodiment, ammonium phosphate accounting for 0.1-0.5% of the weight of fresh fruits and crystallized white granulated sugar accounting for 15% -25% of the weight of the fresh fruits are added to prepare the fermentation mother liquor to adjust the culture conditions; in the preparation of the first fermentation liquor, white granulated sugar which accounts for 15 to 25 percent of the weight of the fresh fruits is added to adjust the sugar degree, and citric acid which accounts for 0.5 to 2.0 percent of the weight of the fresh fruits is added to adjust the acidity.
The fermentation broth obtained by the method for preparing the pokeweed fruit fermentation broth, wherein the fermentation flora of the pokeweed fruit fermentation broth is mainly characterized by eight strains of Penicillium sublaterium, Golubepiallescens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozyma guilliermondii, Candida intermedia, Lodderomyces elengiensis and Aspergillus sydowii.
In a second aspect, the present invention provides a fresh pokeweed fruit fermentation broth obtained according to the above-mentioned preparation method, comprising a mixed species of eight species of bacteria selected from the group consisting of Penicillium sublaterium, Golubevia pallesens, Aspergillus penicillioides, Aspergillus parvus, Meyerozyma guilliermondii, Candida intermedia, loddermyces elongisporus, and Aspergillus sywii, wherein the abundance of each species in the fermentation broth is increased by at least 100-fold or more compared to the fresh fruit before fermentation.
In a third aspect, the present invention provides a pokeweed fruit fermentation broth containing, as active ingredients, anthraquinones and glycosides thereof including compounds of formulae (a) to (F) and pokeweed polysaccharides consisting of arabinose (Ara), rhamnose (Rha), galacturonic acid (GalUA), mannose (Man), glucose (Glc) and galactose (Gal) in a molar ratio of 12: 6: 1: 20: 30: 36;
the fresh pokeweed fruit fermentation broth is prepared from fresh pokeweed fruit by taking mixed bacteria of eight bacteria including Penicillium sublateritium, Golubeva pallesens, Aspergillus penicillioides, Aspergillus parvus, Meyerozymea guilliermondii, Candida intermedia, Lodderomyces elongii and Aspergillus sydowii as fermentation strains.
In a fourth aspect, the present invention provides a fermentation broth of fresh pokeweed fruit, the broth being prepared from a mixture of eight species of pokeweed fruit, including Penicillium sublateritium, Golubeva pallesens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozyma guilliermondii, Candida intermedia, Loddermyces elongii and Aspergillus sydowii.
The fermentation process is a complex biochemical reaction process taking specific strains as cores, so certain environmental conditions are required. In order to further illustrate the present invention, the fermentation conditions of the method for preparing the pokeweed fruit fermentation liquid are characterized in that, in addition to adopting a proper fermentation strain: mature and fresh pokeberry is adopted, and the pokeberry fresh fruit cannot be mildewed or rotten; the first fermentation day is 30-60 days, and the fermentation temperature is 20-30 ℃; the second fermentation day is more than 30 days, the sugar degree, acidity and inorganic salt content of the fermentation liquor, and the temperature, humidity and dissolved oxygen of the environment can be properly adjusted to ensure that the fermentation of the strains characterized by 8 strains can be smoothly carried out, and the screened proper humidity is 70-80% of relative humidity and dissolved oxygen.
On the basis, however, the method is not limited to adding other new strains for promoting and ensuring the smooth proceeding of the directional fermentation, and one or a plurality of other strains are added, so that the fermentation results of dominant strains cannot be obviously different, and the method falls into the invention.
In addition, any one of Penicillium sublateritium, Golubeevia pallesens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozyma guilliermondii, Candida intermedia, Lodderomyces elongisporus and Aspergillus sydowii and/or a mixed strain of any combination of two or more of them is used as the fermentation broth prepared by the fermentation strain, and it also falls into the present invention.
In a fifth aspect, the present invention provides a use of the aforementioned fresh pokeberry fruit fermentation broth in the preparation of a medicament for treating a disease selected from cancer, aids, arteriosclerosis and skin diseases.
In a sixth aspect, the invention provides an application of the fermented pokeberry fruit liquid in preparing a medicament for treating cancer, which is characterized in that the cancer is selected from liver cancer, lung cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, endometrial cancer and prostate cancer, and is preferably liver cancer.
Further, the medicine can be prepared into oral liquid preparations or solid preparations, and the solid preparations are selected from tablets, capsules and granules.
In a seventh aspect, the present invention provides a use of the fermented liquid of fresh pokeberry fruit in the preparation of non-therapeutic food, drink or health food.
In an eighth aspect, the present invention provides a non-therapeutic food or drink comprising the fermented liquid of fresh pokeweed fruit described above.
In a ninth aspect, the usage of the pokeberry fruit fermentation liquid of the invention: the pokeberry root fermentation liquor can be directly prepared into an oral liquid preparation; or extracting, purifying, drying, and making into extract, dried product or solid, and adding pharmaceutically acceptable excipient or adjuvant into the extract, dried product or solid to make into other medicinal preparations, health products, foods, etc.
Drawings
FIG. 1 comparison of species level heat maps of fresh fruit juice (PAR-1), fermentation mother liquor, and first and second fermentation broth (PAR-2) strains
FIG. 2 structural formula of small molecule component in pokeberry fermentation liquid
FIG. 3 the effect of fermentation broth of Phytolacca acinosa on the tumor weight of H22 hepatoma bearing mice
Advantageous effects
The fresh pokeberry fruit fermentation liquid prepared by the method has definite fermentation strain, controllable fermentation process, stable quality of the fermentation liquid, definite pharmacological active ingredients and obvious treatment effect on cancer.
Detailed Description
EXAMPLE 1 preparation of fermented Phytolacca acinosa fruit liquid
Preparation of fermentation mother liquor: crushing fresh and mature Phytolacca acinosa fruits, naturally fermenting, continuously stirring, adding ammonium phosphate accounting for 0.1-0.5% of the weight of the fresh fruits and crystallized white granulated sugar accounting for 16% of the weight of the fresh fruits, adjusting culture conditions, and performing aerobic fermentation to obtain fermentation mother liquor.
Preparing a first fermentation liquid: 200kg of fresh mature pokeberry is taken, cleaned, drained and dried in the shade until the six seven fruits become dry for later use. Putting the clean pokeberry fruit into a PVC plastic barrel, and adding fermentation mother liquor accounting for 2-3% of the fresh fruit mass. Adding white granulated sugar accounting for 15-25% of the weight of the fresh fruits for sugar degree adjustment, and adding citric acid accounting for 0.5-2% of the weight of the fresh fruits for acidity adjustment. Carrying out aerobic fermentation for 30-60 days at 20-30 ℃, and separating or squeezing to separate fermentation liquor to obtain the fermented liquid.
Preparing a second fermentation liquid: and placing the first fermentation liquid in a PVC plastic barrel, standing, settling, keeping out of the sun, storing, performing anaerobic fermentation, performing full fermentation for more than 30 days to obtain a second fermentation, and separating to obtain supernatant fermentation liquid, namely the pokeberry fruit fermentation liquid.
Example 2 identification of Phytolacca acinosa Zymobacter
The identification of the fermentation strain of the invention comprises the following steps:
sampling: respectively taking 3ml of each of the fresh fruit sample and the pokeberry fruit fermentation liquid sample in the example 1 by using a freezing tube, directly putting the samples into liquid nitrogen for quick freezing for 1h, then labeling the freezing tube with a sealing bag, subpackaging, and putting the samples into a refrigerator at the temperature of-80 ℃ for storage.
2. Extracting genome DNA, wherein the extraction step comprises:
1) subjecting the sample to homogenization and lysis: adding 0.25-0.5 g of sample and 0.6mL of Buffer SOL into 2mL of beads Tube, and carrying out vortex for 5-10 min at the highest speed on a vortex instrument; add 60. mu.L Buffer SDS to the sample and vortex for 15 s.
2) Further lysis of the bacteria: placing the sample into a 70 ℃ water bath kettle, keeping the temperature for 10min, and centrifuging for a short time to collect liquid drops on the tube wall.
3) Add 200. mu.L Buffer PS and 150. mu.L adsorbent Solution to the lysate, vortex and mix well for 20s, stand at room temperature for 5min, occasionally invert 2-3 times during this period, centrifuge for 5min at 13 kg.
4) Transferring the supernatant to a 2mL centrifuge tube, adding equal volume of Buffer GDP, and reversing and mixing to prepare a mixed solution. And (3) loading the DNA column into a collecting pipe, transferring half of the mixed solution in the centrifugal pipe to the DNA column, centrifuging for 30-60 s for 13kg, pouring out the effluent, transferring the remaining mixed solution to the DNA column, repeating the centrifuging operation, pouring out the effluent, and loading the DNA column into a collecting pipe.
5) Adding 400 mu L of Buffer GDP to the DNA column, centrifuging for 30-60 s at 13kg, pouring the effluent, and loading the DNA column into a collection pipe.
6) Then 600. mu.L of Buffer GDP was added to the DNA column, 13kg was centrifuged for 30 to 60 seconds, and the effluent was discarded and the DNA column was collected in a collection tube.
7) And 6, repeating the step.
8) The DNA column is placed in a 1.5mL centrifuge tube, 50 μ L of AE preheated to 70 ℃ Buffer is added to the center of the membrane of the column, the column is placed for 3-5 min, and 13kg is centrifuged for 1 min. The DNA binding column was discarded and the DNA was stored in a refrigerator at 2-8 ℃.
9) The primer sequence is as follows:
GATGAAGAACGYAGYRAATCCTCCGCTTATTGATATGC, PCR amplification of the target region is performed, and the amplified product is recovered and quantified.
3. 16S, ITS sequencing of DNA, library expansion, database search: library quantification and sequencing the second round of amplification products were purified using AMPure XP Beads, quantified using an ABI StepOnePelus Real-Time PCR System (Life Technologies, USA of origin), and sequenced on a Pooling machine according to the PE250 model of Hiseq 2500.
4. Sequencing results
According to the abundance value of the strains, the main fermentation strains in the fermentation liquor of the fresh pokeweed fruits after fermentation are finally determined to be eight strains of Penicillium sublateritium, Golubeva pallesens, Aspergillus penicillioides, Aspergillus parvul, Meyerozyma guilliermondii, Candida intermedia, Lodderomyces elengisporus and Aspergillus sydowii. Wherein Penicillium sublaterium is 1 species of Penicillium; golubeva pallesens, Meyerozyma guilliermondii, Candida intermedia, Lodderomyces elongisporus are yeasts; aspergillus penicilloides, Aspergillus parvus and Aspergillus sydowii are Aspergillus species. The heat map of strain level of fresh fruit liquid (marked as PAR-1) and fermentation broth (marked as PAR-2) is shown in figure 1, and the abundance of strain level of fresh fruit liquid (PAR-1) and fermentation broth (PAR-2) is shown in Table 1.
TABLE 1 seed-level abundance of fresh fruit juice (PAR-1) and fermentation broth (PAR-2) strains
EXAMPLE 3 preparation of fermented liquid of fresh Phytolacca acinosa fruit
Fermenting with 8 strains
200kg of fresh and mature Phytolacca acinosa fruits are cleaned, water is drained, the Phytolacca acinosa fruits are dried in the shade to be six-seven dry, the dried Phytolacca acinosa fruits are placed in a PVC plastic barrel, eight strains of Penicillium sublaterium, Golubepalascens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozymea guillieri, Candida intermedia, Lodderomyces elongii and Aspergillus sydowii are added, the sugar degree and the acidity of the fermentation liquor are adjusted according to the titer ratio of 3.37:3.31:2.32:2.16:1.52:1.45:1.11:1 in sequence, 2.5kg of white granulated sugar and 0.6kg of citric acid are added, the temperature in the daytime is 25-30 ℃, the temperature is 19-27 ℃, and after 30 days of fermentation at night, the first-time fermentation liquor is prepared by squeezing with gauze.
And placing the obtained first fermentation liquid in a clean PVC plastic barrel, sealing and avoiding light, carrying out anaerobic fermentation, standing, carrying out secondary fermentation for 30 days at the daytime temperature of 15-27 ℃ and the nighttime temperature of 8-20 ℃, fully settling, and removing precipitates to obtain a second fermentation liquid, namely the pokeberry fruit fermentation liquid fermented by 8 strains. The pokeberry fruit fermentation liquor can be directly prepared into an oral liquid preparation and can also be used as a raw material.
EXAMPLE 4 preparation of fermented Phytolacca acinosa fruit liquid
Adopting 8 strains and 2 strains for mixed fermentation
200kg of fresh and mature Phytolacca acinosa fruits are cleaned, drained, dried in the shade to six-seven dry, placed in a PVC plastic barrel, added with Penicillium sublateritium, Golubevillescens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozymea guillieri, Candida intermedia, Lodderomyces elosporus and Aspergillus sydowii, and added with Candida parapsilosis and Malassezia restica according to the titer ratio of 3.37:3.31:2.32:2.16:1.52:1.45:1.11:1:0.5:0.5 in sequence, fermented together with 10 strains, added with 2.5kg of white granulated sugar and 0.6kg of citric acid, fermented at the temperature of 25-30 ℃ for fermentation, and the fermentation broth is separated at the temperature of 30-19 ℃ for the first time, and the fermentation broth is fermented at the temperature of 25-19 ℃ for the first time.
And placing the obtained primary fermentation liquid in a clean PVC plastic barrel, sealing and avoiding light, carrying out anaerobic fermentation, standing, carrying out secondary fermentation for 60 days at the daytime temperature of 15-27 ℃ and the nighttime temperature of 8-20 ℃, fully settling, and removing precipitates to obtain secondary fermentation liquid, namely the pokeberry fruit fermentation liquid.
Example 5 isolation and characterization of active ingredients in fermented fresh Phytolacca acinosa fruit solution
In order to further explain the material composition of the target fermentation liquor, the invention analyzes and identifies the chemical micromolecule components and the polysaccharide macromolecule components of the fermentation liquor obtained by fermenting the pokeberry fruit by adopting 8 mixed strains.
1. Isolation and characterization of active ingredients of small molecule drugs
Taking the pokeberry fruit fermentation liquid prepared in the example 2, freeze-drying, adding a proper amount of ethanol to ensure that the alcohol concentration is 80-85%, standing and alcohol precipitating, repeating the steps once, combining the supernatant, carrying out reduced pressure rotary evaporation and concentration until no alcohol smell exists, adding mass spectrum methanol to dilute the solution to 10ul/ml, and carrying out Q-TOF-MS analysis. The main component analysis of the data is carried out by Marker View software, the data is collected in an anion mode, the compound is screened according to the accurate mass number and the isotope kurtosis ratio by Peak View2.0/Masterview1.0 software, then the cracking rule analysis is carried out by comparing a reference product and a reference product secondary spectrogram in a Natural products HR-MS/MS Spectral Library 1.0software, the component composition of the fermentation liquor is determined, and the result is shown in Table 2.
TABLE 2 MS2 of sample based on ESI-QTOF
The structural formula of each compound is obtained by database retrieval, and the compounds are identified as quinones and their glycosides A-F, and the results are shown in figure 2.
2. Analysis of macromolecular polysaccharide component of pokeberry fermentation liquor
Taking the pokeberry fruit fermentation liquid prepared in the example 2, freezing and drying, adding a small amount of water for redissolving, adding a proper amount of ethanol to ensure that the alcohol concentration is 80%, standing and precipitating with ethanol, and repeating the steps for three times to obtain total polysaccharide precipitate. Further adopting a Sevage method to remove protein, dialyzing with running water for 48h, dialyzing with pure water for 24h to remove small molecules, and freeze-drying to obtain the refined total polysaccharide. And (3) performing monosaccharide composition analysis by adopting complete acid hydrolysis, pre-column derivatization and a GC-MS method. The polysaccharide in the pokeweed fruit fermentation liquor mainly comprises arabinose (Ara), rhamnose (Rha), galacturonic acid (GalUA), mannose (Man), glucose (Glc) and galactose (Gal) according to the molar ratio of 12: 6: 1: 20: 30: 36, wherein the content of galactose and glucose is higher, and the content of mannose, rhamnose and galacturonic acid is lower.
Example 6 study of antitumor Effect of Phytolacca acinosa fruit fermentation broth on H22 tumor-bearing mice
Reagent testing: freeze-drying the pokeberry root fermentation liquor to obtain a freeze-dried product of the fermentation liquor, and re-dissolving a certain amount of pure water into suspension with low (0.75g/kg), medium (1.5g/kg) and high (3g/kg) doses according to the mass of the freeze-dried product for administration. Positive drugs: cyclophosphamide, administered at 0.07 g/kg.
Tumor strain: mouse H22 hepatoma cell line, purchased from Shanghai Rich-Duty Biotech, Inc. Inoculating H22 cell with good growth state into abdominal cavity of mouse, inoculating 0.2ml, continuously passaging in vivo for 3 times, collecting ascites of mouse with obvious abdominal expansion, adding appropriate amount of normal saline, and adjusting cell density to 1 × 107One/ml, as an inoculum for H22 tumor-bearing mice.
Animal and model: SPF grade ICR mice, each half male and female, weight 17.3-30.5g, provided by the laboratory animal center of Heilongjiang university of traditional Chinese medicine, and the qualification certificate number: SCXK Black: 2013-004. The inoculation is carried out under the armpit of the mice, and 50 mice are randomly divided into a pokeweed fruit fermentation liquid low, medium and high dose group, a cyclophosphamide group and a model control group (equal volume of normal saline) according to sex and weight.
The administration method comprises the following steps: the body mass of the mice was recorded daily, once daily for 14 days starting on the third day after the inoculation of the mice, and after the last administration, subcutaneous tumor tissues were dissected and weighed.
The statistical method comprises the following steps: tumor inhibition rate (%) (1-administration tumor weight/model tumor weight) × 100%
Statistical processing is carried out by adopting SPSS16.0, and data are all adoptedData between groups are shown to be compared by one-way anova.
The results are shown in Table 3.
Note: comparison with before administration**P<0.01; comparison with the Cyclophosphamide group▲P<0.05
As can be seen from table 3, there was no significant difference in body weight between groups before dosing (P > 0.05); after 14 days of administration, the body weight of each group is respectively compared with that before administration, the body weight of the cyclophosphamide group is obviously reduced (P is less than 0.01), and the pokeberry root fermentation broth has no obvious difference in each group; after 14 days of administration, the pokeberry fruit fermentation liquid groups have obvious difference (P <0.05) compared with the cyclophosphamide group in the pokeberry fruit fermentation liquid low-dose groups.
Note: comparison with model group*P<0.05,**P<0.01
As can be seen from Table 4, after 14 days of administration, the tumor weights of the respective administration groups were significantly reduced as compared with the model group (*P<0.05;**P<0.01); compared with the model group, the tumor inhibition rates of the pokeberry root fermentation liquid in the high, medium and low dose groups are 47.45%, 32.66% and 42.88% respectively. The tumor volume of the mice in the administration group is obviously smaller than that of the mice in the model group, and the influence of the pokeberry root fermentation liquid on the tumor weight of the H22 liver cancer tumor-bearing mice is shown in figure 3.
Example 7 preparation of fermented liquid of fresh pokeberry fruit for oral liquid preparation
Directly filling the prepared pokeberry fruit fermentation liquid into a 50ml brown light-proof straight-mouth glass bottle in an oral liquid filling production line to prepare oral liquid, and storing the oral liquid in a light-proof shade place.
EXAMPLE 8 preparation of enteric hard Capsule formulation from fermented fresh Phytolacca acinosa fruit
Adding 400g of medicinal anhydrous calcium hydrogen phosphate powder into 5L of fresh pokeberry fruit fermentation liquid, uniformly mixing, freeze-drying to obtain freeze-dried powder, adding 400g of anhydrous calcium hydrogen phosphate powder, uniformly mixing, sieving with a 80-mesh sieve, and filling into enteric hard capsules to obtain the product. The preparation can properly reduce the stimulation effect on the stomach caused by the fermentation of the pokeberry fruit fermentation liquid with higher content of the fermented ethanol and the like.
EXAMPLE 9 preparation of enteric Soft Capsule preparation from fermented liquid of fresh Phytolacca acinosa fruit
Adding 400g of medicinal anhydrous calcium hydrogen phosphate powder into 5L of fresh pokeberry fruit fermentation liquid, uniformly mixing, freeze-drying to obtain freeze-dried powder, adding a proper amount of medicinal auxiliary materials such as emulsifier, grease and the like, preparing a semisolid filling material, and filling the semisolid filling material into enteric soft capsules to obtain the phytolacca acinosa capsule. The preparation can properly reduce the stimulation effect on the stomach caused by the fermentation of the pokeberry fruit fermentation liquid with higher content of the fermented ethanol and the like.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and decorations can be made without departing from the raw material of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A preparation method of a pokeberry fresh fruit fermentation liquid is characterized by comprising the following steps:
(1) preparation of fermentation mother liquor: crushing and fermenting mature and fresh pokeberry fruit, continuously stirring, optionally adding a proper amount of inorganic salt and white granulated sugar to adjust culture conditions, and fully fermenting to obtain fermentation mother liquor;
(2) preparation of a first fermentation broth: taking fresh and mature pokeberry fruit, cleaning, draining, drying in the shade until the pokeberry fruit becomes dry, placing in a non-iron fermentation container, adding 2-3% of fermentation mother liquor, uniformly mixing with the pokeberry fruit, carrying out aerobic fermentation for 30-60 days at 20-30 ℃, adding a proper amount of white granulated sugar and organic acid to adjust sugar degree and acidity, and separating fermentation liquor to obtain first fermentation liquor;
(3) preparation of a second fermentation liquid: and placing the primary fermentation liquor in a non-iron container, placing the container in a cold place at 5-25 ℃, sealing in the dark, standing, and fully fermenting for more than 30 days under an anaerobic condition to obtain secondary fermentation liquor, namely the pokeberry fruit fermentation liquor.
2. The preparation method according to claim 1, characterized in that ammonium phosphate accounting for 0.1-0.5% of the weight of fresh fruits and crystallized white granulated sugar accounting for 15% -25% of the weight of fresh fruits are added in the preparation of the fermentation mother liquor to adjust the culture conditions; in the preparation of the first fermentation liquor, white granulated sugar which accounts for 15 to 25 percent of the weight of the fresh fruits is added to adjust the sugar degree, and citric acid which accounts for 0.5 to 2.0 percent of the weight of the fresh fruits is added to adjust the acidity.
3. A fermented liquid of fresh pokeweed fruit obtained according to the method of claim 1 or 2, characterized in that the fermented liquid of pokeweed fruit contains a mixed species of eight species of bacteria selected from the group consisting of Penicillium sublateritium, Golubevia pallesens, Aspergillus penicilioides, Aspergillus parvulus, Meyerozyma guilliermondii, Candida intermedia, loddermyces elongii and Aspergillus sydowii, wherein the abundance of each species of bacteria in the fermented liquid is increased by at least 100-fold or more compared to the fresh fruit before fermentation.
4. A pokeweed fruit fermentation liquid is characterized in that the fermentation liquid contains anthraquinone and glycosides thereof and pokeweed polysaccharide as active ingredients, wherein the anthraquinone and glycosides thereof comprise compounds of formulas (A) to (F), and the pokeweed polysaccharide consists of arabinose (Ara), rhamnose (Rha), galacturonic acid (GalUA), mannose (Man), glucose (Glc) and galactose (Gal) according to the molar ratio of 12: 6: 1: 20: 30: 36;
5. a fermentation broth according to claim 4, characterized in that it is prepared from fresh Phytolacca acinosa fruit as a fermenting species from a mixture of eight species comprising Penicillium sublateritium, Golubeva pallesens, Aspergillus penicillioides, Aspergillus parvul, Meyerozymea guilliermondii, Candida intermedia, Lodderomyces elongisporus and Aspergillus sydowii.
6. A fermentation broth of fresh pokeweed fruit, wherein the fermentation broth is prepared from the fermentation of fresh pokeweed fruit with a mixture of eight bacteria comprising Penicillium sublateritium, Golubeva pallesens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozymea guilliermondii, Candida intermedia, Loddeplomyces elengiensis and Aspergillus sydowii.
7. Use of a mixture of bacteria comprising eight bacteria of the group consisting of Penicillium sublateritium, Golubeva pallesens, Aspergillus penicillioides, Aspergillus parvulus, Meyerozymea guilliermondii, Candida intermedia, Lodderomyces elongii and Aspergillus sydowii as fermenting species for the preparation of a fermented broth of fresh Phytolacca acinosa.
8. Use of a fermented pokeweed fruit broth according to any one of claims 3-6 for the preparation of a medicament for the treatment of a disease selected from the group consisting of cancer, AIDS, arteriosclerosis and skin disorders.
9. Use of a pokeweed fruit broth according to any one of claims 3-6 for the preparation of a medicament for the treatment of cancer selected from liver cancer, lung cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, endometrial cancer, prostate cancer, preferably liver cancer.
10. Use of a fermented pokeweed fruit solution according to any one of claims 3-6 in the preparation of a non-therapeutic food or drink or health food.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011079683.6A CN112190603A (en) | 2020-10-10 | 2020-10-10 | Phytolacca acinosa fruit fermentation liquor and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011079683.6A CN112190603A (en) | 2020-10-10 | 2020-10-10 | Phytolacca acinosa fruit fermentation liquor and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112190603A true CN112190603A (en) | 2021-01-08 |
Family
ID=74013333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011079683.6A Pending CN112190603A (en) | 2020-10-10 | 2020-10-10 | Phytolacca acinosa fruit fermentation liquor and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112190603A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116549499A (en) * | 2023-06-07 | 2023-08-08 | 广东省九转生物医药有限公司 | Application of effective part of pokeberry fermentation broth extract in preparation of antitumor drugs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101513435A (en) * | 2008-11-26 | 2009-08-26 | 靳关生 | Biological preparation formed by utilizing fermentation process for India pokeberry and preparation method |
CN110051710A (en) * | 2019-03-26 | 2019-07-26 | 刘文龙 | Using the drug and preparation method thereof for the raising immune function of human body that Phytolacca acinosa fresh fruit is prepared as raw material |
-
2020
- 2020-10-10 CN CN202011079683.6A patent/CN112190603A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101513435A (en) * | 2008-11-26 | 2009-08-26 | 靳关生 | Biological preparation formed by utilizing fermentation process for India pokeberry and preparation method |
CN110051710A (en) * | 2019-03-26 | 2019-07-26 | 刘文龙 | Using the drug and preparation method thereof for the raising immune function of human body that Phytolacca acinosa fresh fruit is prepared as raw material |
Non-Patent Citations (1)
Title |
---|
肖志美等: "基于网络药理学的商陆水煎液治疗小鼠H22肝癌作用机制研究", 《河南大学学报(医学版) 》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116549499A (en) * | 2023-06-07 | 2023-08-08 | 广东省九转生物医药有限公司 | Application of effective part of pokeberry fermentation broth extract in preparation of antitumor drugs |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108339000B (en) | Panax plant extract, and pharmaceutical composition and application thereof | |
CN113318201A (en) | Health food for reducing uric acid and preparation method thereof | |
CN112535239B (en) | Compound Chinese herbal medicine feed additive for daily health care and growth promotion of livestock and preparation and application thereof | |
CN1861637A (en) | Preparation process of Huai Chinese yam polysaccharose and use thereof | |
CN112190603A (en) | Phytolacca acinosa fruit fermentation liquor and preparation method and application thereof | |
CN112190644A (en) | Plant fermentation product, preparation method thereof and application of plant fermentation product in stomach health care | |
CN108456258B (en) | Preparation method of dendrobium officinale selenium polysaccharide | |
CN101433575B (en) | Chinese sapium bark seed extract and preparation method thereof | |
CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
KR102472951B1 (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
CN111150754B (en) | Application of chestnut flower extract in preparation of food or anti-inflammatory drugs | |
CN114053390B (en) | Traditional Chinese medicine composition with hypoxia tolerance and preparation method and application thereof | |
CN106728962B (en) | Pharmaceutical composition for enhancing immunity and application thereof | |
CN114681573B (en) | Method for preparing traditional Chinese medicine by utilizing composite microorganism fermentation liquor, composition and application thereof | |
CN111789252A (en) | Method for improving kidney-tonifying and yang-strengthening effects of maca by enzymolysis fermentation method | |
CN105454956A (en) | A hericium erinaceus-common cattail solid fermentation functional drink and a preparing method | |
CN108159162B (en) | Fermentation product containing magnolia bark bulk drug and preparation method and application thereof | |
CN110575459A (en) | preparation method of coprophilous fungi transplanting capsule | |
CN116036174B (en) | Medicine for treating pulmonary nodules and preparation method thereof | |
CN115282185B (en) | Fermented salvia miltiorrhiza extract containing salvia miltiorrhiza enzymes, and preparation method and application thereof | |
CN104146244B (en) | Not old careless oral liquid of a kind of wilsonii and preparation method thereof | |
CN115770252B (en) | Polygonatum sibiricum polysaccharide composition and preparation method and application thereof | |
CN108314746B (en) | Dendrobium officinale selenium polysaccharide | |
CN107412607B (en) | Asparagus capsule and preparation method thereof | |
CN109453128B (en) | Composition of fermented cordyceps sinensis powder Cs-4 and American ginseng and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |